\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

^{[1]<\/sup> Shah SJ, Borlaug B, Kitzman D, et al<\/em>. Research priorities for heart failure with preserved ejection fraction. Circulation<\/em>. 2020;141:1001–26.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[2]<\/sup> Andersen MJ, Borlaug BA. Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep<\/em>. 2014 Jul;16(7):501.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[3]<\/sup> GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet.<\/em> 2018;392(10159):1789–858.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[4] <\/sup>Solomon S, Dobson J, Pocock S, et al<\/em>. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation<\/em>. 2007;116(13):1482–7.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[5]<\/sup> American Heart Association. Types of Heart Failure. Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/types-of-heart-failure. Accessed: July 2021<\/span><\/p> <\/td> \n <\/tr> \n}

^{[6]<\/sup> ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951<\/a>. Accessed: July 2021.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[7]<\/sup> Packer M, Anker SD, Butler J, et al<\/em>. Cardiac and Renal Outcomes With Empagliflozin in Heart Failure With a Reduced Ejection Fraction. N Engl J Med.<\/em> 2020;383:1413–24.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[8]<\/sup> Jardiance^{®<\/sup> (empagliflozin) tablets, U.S. Prescribing Information. Available at: http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf<\/a>. Accessed: July 2021.<\/span><\/p> <\/td> \n <\/tr> \n}}

^{[9]<\/sup> Jardiance® (empagliflozin) tablets. European Product Information, approved April 2020. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jardiance-epar-product-information_en.pdf<\/a>. Accessed July 2021.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[10]<\/sup> Jardiance^{®<\/sup> (Full Prescribing Information). Mexico; Boehringer Ingelheim Pharmaceuticals, Inc; 2017.<\/span><\/p> <\/td> \n <\/tr> \n}}

^{[11]<\/sup> ClinicalTrials.gov. EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509674<\/a>. Accessed July 2021.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[12]<\/sup> ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03594110<\/a>. Accessed: July 2021.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[13]<\/sup> ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057977<\/a>. Accessed: July 2021.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[14]<\/sup> American Heart Association. Ejection Fraction Heart Failure Measurement. Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/diagnosing-heart-failure\/ejection-fraction-heart-failure-measurement<\/a>. Accessed: July 2021.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[15] <\/sup>GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet<\/em>. 2016; 388(10053):1459–544.<\/span><\/p> <\/td> \n <\/tr> \n}

[16] American Heart Association. What is Heart Failure? Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure<\/a>. Accessed: July 2021.<\/span><\/p> <\/td> \n <\/tr> \n

^{[17]<\/sup> Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. <\/em>2019;124(1):121–41.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[18]<\/sup> Dunlay SM, Givertz MM, Aguilar D, et al.<\/em> Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America. Circulation.<\/em> 2019;140:e294–e324.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[19]<\/sup> García-Donaire JA, Ruilope LM. Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol<\/em>. 2011;2011:975782.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[20]<\/sup> Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes<\/em>. 2015;6(13):1246–58.<\/span><\/p> <\/td> \n <\/tr> \n}

^{[21]<\/sup> Thomas M, Cooper M, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. <\/em>2015;12:73–81.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}

<\/p>"]; $("#dvExtra").html(content_array[0]);})();